RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
  Dialysis
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Dialysis Channel

subscribe to Dialysis newsletter
Latest Research : Nephrology : Dialysis

   EMAIL   |   PRINT
Dialysis patients may be overmedicated

Nov 30, 2005 - 3:35:00 PM
"careful attention to the comparability of PTH assays is required by nephrologists and those who serve patients in this area."

 
[RxPG] Changes in a widely used assay (blood test) for parathyroid hormone (PTH) have made its use with the established guidelines for end stage renal disease clinical management both inappropriate and potentially harmful to patients. This research is published in the journal Seminars in Dialysis.

A PTH assay measures levels of parathyroid hormone, produced by the parathyroid gland, which helps diagnose conditions such as hyperparathyroidism or to determine causes of abnormal regulation of calcium by the bones of patients with renal disease, which can lead to arterial calcification. Levels of PTH that are too high or too low can affect calcium metabolism, bone integrity and cause vascular disease.

In 2003, the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) published the Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. These guidelines, for both diagnoses and treatments, are based on use of a manual iPTH assay that is not widely used for routine clinical analysis.

According to an editorial in Seminars in Dialysis, the iPTH assay that is now widely used by nephrologists has shifted significantly compared to the assay on which K/DOQI guidelines are based, generating much different results. Currently, almost all testing of dialysis patient specimens in the United States are performed at one of seven centralized labs. None use the PTH test on which the K/DOQI bone metabolism guidelines are based.

As a result, evidence shows that rates of parathyroidectomy may have been increased, patients have been over treated with expensive medications, and adynamic bone disease has become more prevalent, now affecting half of dialysis patients.

Tom Cantor, author of the editorial, and his research team have tracked changes in the most commonly used PTH assay. The team has also developed a more specific assay for PTH.

They have found important inconsistencies in testing results, Cantor states, indicating that "careful attention to the comparability of PTH assays is required by nephrologists and those who serve [patients] in this area."



Publication: This study is published in Seminars in Dialysis.
On the web: www.blackwellpublishing.com 

Advertise in this space for $10 per month. Contact us today.


Related Dialysis News
Intradialytic hypotension associated with increased incidence of haemodialysis vascular access thrombosis
Low Phosphate diet not helpful in dialysis patients
Nephrologist care prior to starting dialysis reduces risk of death
Lower death rate in dialysis patients living at higher altitude
Clear advantage of high efficacy Haemodiafiltration over conventional hemodialysis
Dialysis patients may be overmedicated
Dialysis patients often have close family members also on dialysis - Study
Hemodialysis causes antioxidant loss leading to long-term complications
Oxidative Stress in Dialysis Patients can Lead to Long-Term Health Problems

Subscribe to Dialysis Newsletter

Enter your email address:


 Additional information about the news article
About the Journal
Seminars in Dialysis is a bimonthly publication focusing exclusively on cutting-edge clinical aspects of dialysis therapy. Besides publishing papers by the most respected names in the field of dialysis, the Journal has unique useful features, all designed to keep you current: dialysis clinic, dialysis rounds, hemodialysis citations, editorials, opinions, brief notes.

About Blackwell Publishing
Blackwell Publishing is the world's leading society publisher, partnering with more than 600 academic and professional societies. Blackwell publishes over 750 journals annually and, to date has published close to 6,000 text and reference books, across a wide range of academic, medical, and professional subjects.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)